| pubmed-article:15006407 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15006407 | lifeskim:mentions | umls-concept:C0242350 | lld:lifeskim |
| pubmed-article:15006407 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15006407 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:15006407 | lifeskim:mentions | umls-concept:C0034424 | lld:lifeskim |
| pubmed-article:15006407 | lifeskim:mentions | umls-concept:C1318700 | lld:lifeskim |
| pubmed-article:15006407 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:15006407 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15006407 | pubmed:dateCreated | 2004-3-9 | lld:pubmed |
| pubmed-article:15006407 | pubmed:abstractText | In a continuing effort to discover novel chemotypes as potent and selective PDE5 inhibitors for the treatment of male erectile dysfunction (ED), we have found that 4-benzylaminoquinoline derivatives are very potent and selective PDE5 inhibitors. Some compounds in this series had PDE5 IC(50)'s as low as 50 pM. While an electron withdrawing group at the C6-position of the quinoline substantially improved PDE5 potency, an ethyl group at the C8-position not only improved the PDE5 potency but also the isozyme selectivity. Substitutents at the C3-position can incorporate a variety of different groups. The synthesis and primary structure-activity relationship of this new series of potent PDE5 inhibitors are described. | lld:pubmed |
| pubmed-article:15006407 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15006407 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15006407 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15006407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15006407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15006407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15006407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15006407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15006407 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15006407 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15006407 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:HeBinB | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:WatsonAndrewA | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:MacorJohn EJE | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:SeligerLaurie... | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:NormandinDian... | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:AdamLeonardL | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:KrupinskiJohn... | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:BiYingzhiY | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:StoyPatrickP | lld:pubmed |
| pubmed-article:15006407 | pubmed:author | pubmed-author:PongracRonR | lld:pubmed |
| pubmed-article:15006407 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15006407 | pubmed:day | 22 | lld:pubmed |
| pubmed-article:15006407 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:15006407 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15006407 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15006407 | pubmed:pagination | 1577-80 | lld:pubmed |
| pubmed-article:15006407 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15006407 | pubmed:meshHeading | pubmed-meshheading:15006407... | lld:pubmed |
| pubmed-article:15006407 | pubmed:meshHeading | pubmed-meshheading:15006407... | lld:pubmed |
| pubmed-article:15006407 | pubmed:meshHeading | pubmed-meshheading:15006407... | lld:pubmed |
| pubmed-article:15006407 | pubmed:meshHeading | pubmed-meshheading:15006407... | lld:pubmed |
| pubmed-article:15006407 | pubmed:meshHeading | pubmed-meshheading:15006407... | lld:pubmed |
| pubmed-article:15006407 | pubmed:meshHeading | pubmed-meshheading:15006407... | lld:pubmed |
| pubmed-article:15006407 | pubmed:meshHeading | pubmed-meshheading:15006407... | lld:pubmed |
| pubmed-article:15006407 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15006407 | pubmed:articleTitle | Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. | lld:pubmed |
| pubmed-article:15006407 | pubmed:affiliation | Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA. ybi@lexpharma.com | lld:pubmed |
| pubmed-article:15006407 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:15006407 | lld:chembl |
